Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
HBM Holdings Ltd. ( (HK:2142) ) just unveiled an update.
HBM Holdings Ltd. announced its annual results for 2024, highlighting a significant decrease in revenue from $89.5 million in 2023 to $38.1 million in 2024, alongside a reduction in research and development expenses. The company reported a profit of $2.7 million for the year. Key business developments include the acceptance of a Biologics License Application for Batoclimab in China, the approval of an IND application for HBM9378 for COPD, and ongoing clinical trials for other products, indicating a strategic focus on advancing its therapeutic pipeline.
More about HBM Holdings Ltd.
HBM Holdings Ltd. operates in the biotechnology industry, focusing on the development and commercialization of innovative therapies. The company is engaged in research and development, with a market focus on biologics and treatments for various medical conditions, including generalized myasthenia gravis and chronic obstructive pulmonary disease.
YTD Price Performance: 393.55%
Average Trading Volume: 10,044,309
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.93B
For an in-depth examination of 2142 stock, go to TipRanks’ Stock Analysis page.